Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia

Medical Hypotheses

Volumn 69, Issue 4, 2007, Pages 925-927

  Hosseini, Hamid ^a   Nejabat, Mahmood ^a   Khalili, Mohammad Reza ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; MITOMYCIN C; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BETA RADIATION; DISEASE COURSE; DRUG MECHANISM; DRUG TARGETING; EYE SURGERY; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PTERYGIUM; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PTERYGIUM;

EID: 34547852289     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.01.047     Document Type: Article

References (19)

1. Hosseini H., and Nejabat M. A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. Med Hypotheses 68 4 (2007) 799-801
2. Zhang S.X., and Ma J.X. Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 26 1 (2007) 1-37
3. Jin J., Guan M., Sima J., Gao G., Zhang M., Liu Z., et al. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea 22 5 (2003) 473-477
4. Hirst L.W. The treatment of pterygium. Surv Ophthalmol 48 2 (2003) 145-180
5. Prabhasawat P., Tesavibul N., Leelapatranura K., and Phonjan T. Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology 113 7 (2006) 1102-1109
6. Hill J.C., and Maske R. Pathogenesis of pterygium. Eye 3 Pt 2 (1989) 218-226
7. Cameron M.E. Histology of pterygium: an electron microscopic study. Br J Ophthalmol 67 9 (1983) 604-608
8. Di G.N., Coroneo M.T., and Wakefield D. Active matrilysin (MMP-7) in human pterygia: potential role in angiogenesis. Invest Ophthalmol Vis Sci 42 9 (2001) 1963-1968
9. Marcovich A.L., Morad Y., Sandbank J., Huszar M., Rosner M., Pollack A., et al. Angiogenesis in pterygium: morphometric and immunohistochemical study. Curr Eye Res 25 1 (2002) 17-22
10. Aspiotis M., Tsanou E., Gorezis S., Ioachim E., Skyrlas A., Stefaniotou M., et al. Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. Eye Jun 23 (2006)
11. van S.G., Aspiotis M., Blalock T.D., Grotendorst G., and Schultz G. Connective tissue growth factor in pterygium: simultaneous presence with vascular endothelial growth factor - possible contributing factor to conjunctival scarring. Graefes Arch Clin Exp Ophthalmol 241 2 (2003) 135-139
12. Gebhardt M., Mentlein R., Schaudig U., Pufe T., Recker K., Nolle B., et al. Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. Ophthalmology 112 6 (2005) 1023-1030
13. Lee D.H., Cho H.J., Kim J.T., Choi J.S., and Joo C.K. Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea 20 7 (2001) 738-742
14. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 5 (2004) 391-400
15. Aisenbrey S., Ziemssen F., Volker M., Gelisken F., Szurman P., Jaissle G., et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol Dec 21 (2006)
16. Iliev M.E., Domig D., Wolf-Schnurrbursch U., Wolf S., and Sarra G.M. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 142 6 (2006) 1054-1056
17. Jorge R., Costa R.A., Calucci D., Cintra L.P., and Scott I.U. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26 9 (2006) 1006-1013
18. Jorge R., Costa R.A., Calucci D., and Scott I.U. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol Nov 29 (2006)
19. Manzano R., Peyman G., Khan P., Carvounis P., Kivilcim M., Ren M., et al. Inhibition of experimental corneal neovascularization by Bevacizumab(AVASTIN). Br J Ophthalmol Dec 19 (2006)